HLA Genotyping in Patients with End-Stage Renal Disease Waiting For Cadaveric Renal Transplantation in Federation of Bosnia and Herzegovina

Elma Fejzić1, Jasenko Karamehić2, Izet Eminović3, Damir Suljević3, Andi Alijagić3*, Semir Bečirević4, Amela Šahović1, Sanela Šišić1

1Institute of Transfusion Medicine of Federation of Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina; 2Department of Immunology, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina; 3Department of Biochemistry and Physiology, Faculty of Science, University of Sarajevo, Sarajevo, Bosnia and Herzegovina; 4Institute of Pathology, Clinical Center University of Tuzla, Tuzla, Bosnia and Herzegovina

Abstract

AIM: The research was conducted by genotyping two Human Leukocyte Antigen (HLA) gene classes. The main objective of this research was to investigate distribution and frequency of the allelic groups, genotypes and haplotypes in the gene loci of HLA class I (HLA-A*, -B*, -C*) and HLA class II (HLA-DRB1*, -DQB1*) in patients included in the program of cadaveric renal transplantation.

MATERIAL AND METHODS: Our study covered 186 blood samples of patients who are registered on the list for cadaveric renal transplantation in Federation of Bosnia and Herzegovina and included 59 control, healthy unrelated individuals. For the HLA typing, we have used three different methods: micro lymphocyte cytotoxicity test (MLCT), Polymerase Chain Reaction (PCR) – Sequence Specific Primers (SSP) and PCR – Sequence-Specific Oligonucleotides (SSO) or Luminex technology. All patients and cadaveric donors were tested using the three methods because the system is polymorphic.

RESULTS: Analysis of the results of genotyping HLA class I gene loci identified dominant HLA-A*02, HLA-B*35, HLA-C*07 allelic groups. Analysis of the HLA class II gene loci genotyping showed that HLA-DRB1*11 and HLA-DQB1*03 loci had the highest incidence in HLA class II.

CONCLUSION: Based on our results and previous research, there were no observed differences between allelic frequencies and genotypes of healthy people and people with ESRD. Differences between allelic groups occurred, but they were not statistically significant, except HLA-C*01 (p = 0.020).

Introduction

The main problem with renal transplantation is the lack of suitable dead donors. The improvements in molecular genotyping methods, diagnostics and therapy for maintaining transplants, upgrade the transplantation process, however, the number of dead donors is not increasing, while transplantation lists and the need for dead transplants continues to grow each year [1]. Kidney transplants from live donors produce better results, including faster rehabilitation and better success rate. Another advantage is the increase in the number of available organs. Higher tissue HLA matching between donors and recipients contributes to the longer survival of transplanted organs [2]. Many transplant centres are limited to living organ donors only. When the donors are divided into groups by degree of HLA compatibility with the organ recipient, a better result in the survival of transplant has been achieved in the cases of higher HLA compatibility. This fact is especially true when the unrelated persons (or distant relatives) are kidney donors [3, 4]. Living organ transplantation should be considered for each organ recipient. MHC antigens, which have proven to be important in kidney
transplantation, are HLA-A, HLA-B and HLA-DR markers. As these antigens were determined by the genes of both parents, at least six antigens of the recipient (2A, 2B and 2DR) must correspond with the antigens of the potential donor [5]. If the kidney has been taken from a family member, parents or siblings, it is necessary that there is a correspondence in three loci, and partial coincidence in less important, but other present genes HLA-C, HLA-DP and HLA-DQ [6]. Value of the haplotype synchronizing (0, 1, 2) was determined clinically: siblings with two identical haplotypes can expect survival of 90% of transplants after one year, parents and siblings with the same haplotype after one year achieved graft survival of 75%, and members of the same family without equal haplotypes achieve survival of 50% of the grafts after one year [7]. The main problem in transplantation is the immune response of T and B lymphocytes of the host [8]. The most preferred method for the prevention of transplant rejection is achieving sufficient antigen matching between donor and recipient, as with identical twins. Good acceptance of the transplanted tissue or organ is already achieved if the donor and recipient are matched in MHC-II class of antigens (in particular HLA-DR) since they directly activate T-helper lymphocytes of the recipient [9, 10]. HLA antigens are the main target of immune response which leads to the rejection of transplanted organs. For the purpose of transplantation, a state of the histocompatibility between donor and recipient exists only when the immune response is absent or controlled to foreign graft survive [11]. The reaction of transplant rejection is an immune response, directed primarily towards the molecules of the main histocompatibility system or MHC antigens and other mismatched graft antigens [12, 13].

The main objective of this research was analysis of distribution and frequency of the allelic groups, genotypes and different haplotypes in the gene loci of HLA class I (HLA-A*, -B, -C*) and HLA class II (HLA-DRB1*, -DOB1*) in patients who have been included in the program of cadaveric renal transplantation in Federation of Bosnia and Herzegovina (FB&H) for period 2007-2012.

**Materials and Methods**

The sample included 186 patients. All patients were in End Stage Renal Disease (ESRD) who were included in the program of cadaveric kidney transplantation in FB&H, and they are not related by blood kinship relations. Research covered patients from 9 hemodialysis center: Sarajevo (39 male; 16 women), Zenica (29 male; 12 women), Bihać (13 male; 11 women), Tešanj (13 male; 10 women); Travnik (8 male; 5 women), Mostar +Konjic (4 male; 4 women), Živinice + Gračanica (8 male; 1 women), Odžak (6 male; 2 women). Mean age was 49 ± 7 years. Our research on patients was undertaken in compliance with all applicable guidelines, which aim to ensure the proper implementation of the safety of persons participating in the scientific research, including Fundamentals of Good Clinical Practice, Declaration of Helsinki 1975, as revised in 2008, and in the accordance with the approval of the Ethics Committee of the Institute (Approval No. 01-3-3558 23.6.2016). Genotyping included 59 healthy individuals that are not related to the patients; they represented control group.

**HLA genotyping**

Samples of venous blood were taken into vacutainer tubes with anticoagulant heparin (serological analysis), and samples of venous blood were taken into vacutainer tubes with anticoagulant EDTA (ethylene diamine tetra acetyl acid – molecular analysis). Isolation of DNA was carried out using the kit for DNA, Ready – DNA Spin Kit (Inno-train, Germany). The HLA genotyping was performed by using three different methods: 1) phenotyping of HLA class I (A, B and C) was done by using micro lymphocyte cytotoxicity test (MLCT); 2) genotyping of HLA class I (HLA-A*, -B* and -C*) and HLA class II (HLA-DRB1* and -DOB1*) was performed by low resolution or by using the Polymerase Chain Reaction (PCR) qualitative detection of sequential specific PCR products by agarose gel electrophoresis (method is based on the PCR-SSP or Sequence Specific Primers); 3) genotyping of HLA class I (HLA-A*, -B* and -C*) and HLA class II (HLA-DRB1* and -DOB1*) was also performed by low resolution, using asymmetric PCR with different primers for each sample. After amplification of the PCR products labelled with biotin, they were mixed and bind to complementary probes during hybridization process (method based on PCR-SSO or Sequence-Specific Oligonucleotides). This technology is also called Luminex technology or technology of fluoroanalyser with microspheres.

**Statistical analysis**

The frequency of genotypes, gene variants was estimated according to estimation-maximization (EM) algorithm which has been implemented in a computer software PowerMarker v3.25 (Bioinformatic program, Raleigh, NC, USA) and OpenEpi v3.01. [14]. Software for calculating risk ratios (OR) using 2x2 contingency tables was also used. To calculate the statistical significance of the differences in the frequencies of gene variants, and genotypes of the control group and the patients, the Fisher accuracy test, with P >0.05 was used.
Results

The highest frequency within the HLA-DBQ1* gene locus had allelic group DBQ1*03 (0.3333), and HLA-DBQ1* 06 is very frequently in both group. It was not noticed an absence of any allelic group in HLA-DBQ1* gene locus. Results of analysis of DBQ1* allelic groups are shown in Table 2.

Table 2: Frequency of HLA-DRB1* and HLA-DBQ1* gene loci between control and experimental group

The highest frequency within the HLA-DBQ1* gene locus had allelic group DBQ1*03 (0.3333), and HLA-DBQ1* 06 is very frequently in both group. It was not noticed an absence of any allelic group in HLA-DBQ1* gene locus. Results of analysis of DBQ1* allelic groups are shown in Table 2.

Table 2: Frequency of HLA-DRB1* and HLA-DBQ1* gene loci between control and experimental group

The highest frequency within the HLA-DBQ1* gene locus had allelic group DBQ1*03 (0.3333), and HLA-DBQ1* 06 is very frequently in both group. It was not noticed an absence of any allelic group in HLA-DBQ1* gene locus. Results of analysis of DBQ1* allelic groups are shown in Table 2.

Table 2: Frequency of HLA-DRB1* and HLA-DBQ1* gene loci between control and experimental group

The highest frequency within the HLA-DBQ1* gene locus had allelic group DBQ1*03 (0.3333), and HLA-DBQ1* 06 is very frequently in both group. It was not noticed an absence of any allelic group in HLA-DBQ1* gene locus. Results of analysis of DBQ1* allelic groups are shown in Table 2.

Table 2: Frequency of HLA-DRB1* and HLA-DBQ1* gene loci between control and experimental group

The highest frequency within the HLA-DBQ1* gene locus had allelic group DBQ1*03 (0.3333), and HLA-DBQ1* 06 is very frequently in both group. It was not noticed an absence of any allelic group in HLA-DBQ1* gene locus. Results of analysis of DBQ1* allelic groups are shown in Table 2.

Table 2: Frequency of HLA-DRB1* and HLA-DBQ1* gene loci between control and experimental group

The highest frequency within the HLA-DBQ1* gene locus had allelic group DBQ1*03 (0.3333), and HLA-DBQ1* 06 is very frequently in both group. It was not noticed an absence of any allelic group in HLA-DBQ1* gene locus. Results of analysis of DBQ1* allelic groups are shown in Table 2.

Table 2: Frequency of HLA-DRB1* and HLA-DBQ1* gene loci between control and experimental group

The highest frequency within the HLA-DBQ1* gene locus had allelic group DBQ1*03 (0.3333), and HLA-DBQ1* 06 is very frequently in both group. It was not noticed an absence of any allelic group in HLA-DBQ1* gene locus. Results of analysis of DBQ1* allelic groups are shown in Table 2.
Within the HLA-C* gene locus it was found 37 different genotypes (Table 5), the most common genotypes were HLA-C*07/07*C (0.1774), HLA-C*04/04*C (0.1022) and HLA-C*04/07*C (0.0699) in patients group. In the control group, the most frequent genotype is HLA-C*07/07*C (0.1356).

Table 5: Frequency of HLA-C* genotypes between control and experimental group

| HLA-C* genotypes | n Patients | n Genotype frequency | Control | n Genotype frequency | p-values |
|------------------|-----------|---------------------|---------|---------------------|---------|
| C*01/C*01       | 10        | 0.0538              | /       | /                   |         |
| C*02/C*02       | 7         | 0.0376              | /       | /                   |         |
| C*03/C*03       | 7         | 0.0376              | /       | /                   |         |
| C*04/C*04       | 19        | 0.1022              | 3       | 0.0508              | 0.230   |
| C*06/C*06       | 13        | 0.0699              | 5       | 0.0847              | 0.703   |
| C*07/C*07       | 33        | 0.1774              | 8       | 0.1356              | 0.453   |
| C*01/C*06       | 7         | 0.0376              | /       | /                   |         |
| C*06/C*06       | 12        | 0.0645              | 5       | 0.0847              | 0.086   |

Within the HLA-DRB1* gene locus it was determined the presence of 58 different genotypes, including the most common HLA-DRB1*01/DRB1*11 (0.0430), HLA-DRB1*04/DRB1*11 and HLA-DRB1*13/DRB1*16 genotype (0.0376) in patients group.

Table 6: Frequency of HLA-DRB1* genotypes between control and experimental group

| HLA-DRB1* genotypes | n Patients | n Genotype frequency | Control | n Genotype frequency | p-values |
|---------------------|-----------|---------------------|---------|---------------------|---------|
| DRB1*01/DRB1*11    | 8         | 0.0433              | 1       | 0.0169              | 0.538   |
| DRB1*01/DRB1*04    | 6         | 0.0323              | 1       | 0.0169              | 0.538   |
| DRB1*03(17)/DRB1*11| 6         | 0.0323              | 2       | 0.0339              | 0.950   |
| DRB1*04/DRB1*07    | 6         | 0.0323              | 3       | 0.0508              | 0.508   |
| DRB1*01/DRB1*11    | 7         | 0.0376              | 2       | 0.0339              | 0.894   |
| DRB1*11/DRB1*14    | 6         | 0.0323              | 3       | 0.0508              | 0.508   |
| DRB1*11/DRB1*15    | 6         | 0.0323              | 1       | 0.0169              | 0.538   |
| DRB1*13/DRB1*16    | 7         | 0.0376              | /       | /                   |         |

Research results within the HLA-DQB1* gene locus revealed 27 different genotypes. The most usual genotypes were HLA-DQB1*03/DQB1*05 (0.2204) and HLA-DQB1*02/DQB1*03 (0.1667) in patients group. The genotype HLA-DQB1*02/DQB1*03 is the most frequent in the control group.

Table 7: Frequency of HLA-DQB1* genotypes between control and experimental group

| HLA-DQB1* genotypes | n Patients | n Genotype frequency | Control | n Genotype frequency | p-values |
|---------------------|-----------|---------------------|---------|---------------------|---------|
| DQB1*02/DQB1*02    | 8         | 0.0433              | /       | /                   |         |
| DQB1*02/DQB1*02    | 31        | 0.1667              | 10      | 0.1694              | 0.959   |
| DQB1*02/DQB1*02    | 21        | 0.1129              | 4       | 0.0678              | 0.318   |
| DQB1*02/DQB1*02    | 21        | 0.1129              | 3       | 0.0508              | 0.162   |
| DQB1*02/DQB1*02    | 41        | 0.2204              | 7       | 0.1186              | 0.086   |
| DQB1*02/DQB1*02    | 22        | 0.1182              | 8       | 0.1356              | 0.723   |
| DQB1*02/DQB1*02    | 13        | 0.0699              | 6       | 0.1017              | 0.426   |
| DQB1*02/DQB1*02    | 14        | 0.0753              | 3       | 0.0508              | 0.520   |

Discussion

HLA class I molecules can be found on the surface of all cells that contain the nucleus, while class II of HLA molecules can be constitutively found on the surface of certain types of cells (dendritic cells, macrophages, B-lymphocytes. HLA-DR (not HLA-DQ, -DP, or -DM) is abundantly expressed on the endothelial cells of peritubular and glomerular capillaries [15].

Table 8: Frequency of allelic group with Odds Ratio (OR) and p-values between control and patients group

| Allelic groups | 2n Patients | Allele frequency | Control | 2n Control | OR p-values |
|----------------|-------------|------------------|---------|------------|-------------|
| HLA-C*01       | 41          | 0.11022          | 5       | 0.0424     | 0.279       |
| HLA-C*12       | 9           | 0.02419          | 15      | 0.1271     | 0.1702      |
| HLA-DRB1*13    | 38          | 0.10215          | 20      | 0.1695     | 0.5575      |
| HLA-DQB1*06    | 62          | 0.16667          | 29      | 0.2458     | 0.6138      |

The explanation for the improved survival of kidney allografts in which HLA have good congruence was: lower occurrence of anti-HLA antibodies [16], lower occurrence of alloreactive CD4+ T-cells or absence of direct CD4+ T-cell response to HLA-DR matched graft [17], fewer peptide epitopes stimulate response of T-helper cells of "indirect way" which includes chronic rejection of allograft [18]. HLA matching in HLA-A, HLA-B and HLA-DR loci increases the likelihood of developing a donor antigen-specific regulatory T-cells [19].

Benefits of HLA matching has an impact on different outcomes in terms of number of days spent in hospital, failure of graft function [20, 21], episodes of rejection, the one-year and three-year levels of serum creatinine [22], on prediction of long-term outcome of the disease, on status of patients and on multivariate analysis [23, 24].

Chronic renal failure (CRF) leads in most cases to ESRD, with final result – kidney transplantation process. There is an interest to assess connection of class I and II of HLA antigens with ESRD or CRF renal diseases [25].

In hemodialysis patients that are the part of cadaveric renal transplantation program in FB&H it was observed that the HLA antigens with the greatest frequency were: HLA-A*02 = 0.29301, HLA-B*51 = 0.14516, HLA-C*07 = 0.32258, HLA-DRB1*11 = 0.15323 and HLA-DQB1*03 = 0.48334. The antigens that showed in control group greatest frequency were: HLA-A*02= 0.2977, HLA-B*35= 0.1441, HLA-C* = 0.03051, HLA-DRB1*13 = 0.1695 and HLA-DQB1*03 = 0.3050. In the analysis of allelic groups in each locus, with estimation of the p-value, the allelic group HLA-A* showed no statistically significant difference in the aforementioned allelic groups. Such results were also recorded when comparing the frequencies of allelic groups in HLA-B*. Locus C* showed a statistically significant difference in the frequency of the allelic HLA-C*01 with p = 0.020 and OR = 2.601.
that is considered as an allelic group of high risk, and it showed a difference in the allelic HLA-C*12 with p = 0.0000079. Although the OR value is 0.190, this allelic group can't be considered protective. The HLA-DRB1 locus also showed statistical significance in frequencies in the allelic HLA-DRB1*13 (p = 0.030) with OR = 0.6027, and it is not at risk of developing ESRD. The allelic group HLA- DQB1*06 showed statistical significance (p = 0.028) and OR = 0.6138, and it is not considered as a group of high risk, as shown in Table 3.

Our research covered hemodilysis patients included in program of cadaveric renal transplantation in FB&H. The HLA class I (HLA-A*, -B*, -C*) genotypes with the highest incidence were: A*02/A*02 = 0.1022, B35/B44 = 0.0484, C*07/07 = 0.1774. HLA class II genotypes with highest incidence were: DRB1*01/DRB1*11 = 0.043 and DQB1*03/DQB1*05 = 0.2204.

Based on our results and previous research, there were no observed differences between allelic frequencies and genotypes of healthy people and people with ESRD. Differences between allelic groups occurred, but they were not statistically significant, except HLA-C*01, p = 0.020.

References

1. Karamehić J, Dizdarević Z, et al. Komponente imunog sistema (Components of immune system). In: Karamehić J, Dizdarević Z, et al., editors. Klinička imunologija (Clinical Immunology). Sarajevo: Svjetlost, 2007: pp. 53-62.
2. Hume DM, Merrill JP, Miller BF, Thorne GW. Experiences with renal homotransplantations in humans: report of nine cases. J Clin Invest. 1955;34(2):327. https://doi.org/10.1172/JCI103085 PMid:12333545 PMCID:PMC438633
3. Kramer MR, Sprung CL. Living-related donation in lung transplantation. Ethical con siderations. Arch Int Med. 1995;155(16):1734-8. https://doi.org/10.1001/archinte.1995.00430160054006
4. Tesi R, Beck R, Lambiase L, Haque S, Flint L, Jaife B. Living related small bowel transplantation-donor evaluation and outcome. In: Abstract book of XVI International Congress of the Transplantation Society; Barcelona, Spain, 1996.
5. Hirata M, Terasaki PI. Renal re-transplantation. Clin Transplant. 1994;8:419-33.
6. Đurinović-Bello I, Pasini J, Barasić D, Thune S, Puretic Z, Gerečer M, et al. Early detection of allograft rejection by donor-specific lymphocytes – mediated cytolysis: cloning of cytotoxic lymphocytes from positive patients. Transplantant Proc. 1987;19(6):4285-9. PMid:3314029
7. Busson M, Raffoux C, Bouteiller AM, Betuel H, Cambon-Thomson A, Fizet D, et al. Influence of HLA-A, -B, and -DR matching on the outcome of kidney transplant survival in pre-immunized patients. Transplantation. 1984;38(3):227-9. https://doi.org/10.1097/00007890-198409000-00006 PMid:6382711
8. Salvaterra Jr O, Melzer J, Potter D, Garovoy M, Vincent F, Amend WP, et al. Seven-year experience with donor-specific blood transfusions (DST): Results and considerations for maximum efficacy. Transplantation. 1986;40:654-8. https://doi.org/10.1097/00007890-198512000-00016
9. Abbas AK, Lichtman AH. Basic Immunology: Functions an Disorders of the Immune System. New York: Elsevier Inc., 2006-2007: pp. 161-77.
10. Abbas KA, Lichtman HA. Basic Immunology. 2nd ed. Beograd: Data status, 2007: pp. 48-51.
11. Lakkis FG. Transplantation immunobiology. In: Karamehić J, and contributing authors, editors. Transplantation of kidney. University of Sarajevo-Yale University, 2004: pp. 57-68. PMCID:PMC311434
12. Janeway CA, Travers P, Walport M, Shlomchik M, editors. The Immune system in health and disease. In: Immunobiology. New York: Garland Publishing, 2005: pp. 557-96.
13. Janeway CA, Travers P, Walport M, Shlomchik M, editors. Extrinsic regulation of unwanted immune responses. In: Immunobiology. New York: Garland Science Publishing, 2005: pp. 613-30.
14. Liu K, Spencer VM. PowerMarker: an integrated analysis environment for genetic marker analysis. Bioinformatics. 2007;23(9):1219-26. https://doi.org/10.1093/bioinformatics/btm282 PMid:17505655
15. Muczynski KA, Cotner T, Anderson SK. Unusual expression of human lymphocyte antigen class II in normal renal microvascular endothelium. Kidney Int. 2001;59(2):488-97. https://doi.org/10.1046/j.1523-1755.2001.059002488.x PMid:11168931
16. Terasaki PI. Humoral theory of transplantation. Am J Transplant. 2003;3(6):665-73. https://doi.org/10.1034/j.1600-6143.2003.00135.x PMid:12780557
17. Vandekerckhove BA, Datema G, Zantvoort F, Claas FH. An increase of donor-specific T helper precursors resulting from blood transfusions. Transplantation. 1990; 49(5): 987-90. https://doi.org/10.1097/00007890-199005000-00029 PMid:2139988
18. Ciobotariu R, Liu Z, Colovai AI, Ho E, Itescu S, Ravalli S, et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest. 1998;101(2):398. https://doi.org/10.1172/JCI11117 PMid:9453312 PMCID:PMC508579
19. Rodriguez DS, Jankowska-Gan E, Haynes LD, Leveson G, Munoz A, Heisey D, et al. Immune regulation and graft survival in kidney transplant recipients are both enhanced by human leukocyte antigen matching. Am J Transplant. 2004;4(4):537-543. https://doi.org/10.1111/j.1600-6143.2004.00385.x PMid:15023145
20. Gjertson DW. Impact of delayed graft function and acute rejection on kidney graft survival. In: Terasaki P, editor. Clinical Transplants. Los Angeles: UCLA Immunogenetics Center, 2001: pp. 467.
21. Shoskes DA, Cecka JM. Effect of delayed graft function on short- and longterm kidney graft survival. In: Terasaki P, editor. Clinical Transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1997: pp. 297. PMid:9919413
22. Gjertson DW. Two-factor reference tables for renal transplantation. In: Terasaki P, editor. Clinical Transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1996: pp. 433.
23. Takemoto SK, Cho YW, Gjertson DW. Transplant risks. In: Terasaki PI, editor. Clinical Transplants. Los Angeles: UCLA Immunogenetics Center, 2000: pp. 325.
24. Cho YW, Terasaki PI. Impact of new variables reported to the UNOS registry. In: Terasaki P, editor. Clinical Transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1998: pp. 305.
25. Crispim JC, Mendes-Junior CT, Wastowski IJ, Palomino GM, Saber LT, Rassi DM, Donadi EA. HLA polymorphisms as incidence factor in the progression to end-stage renal disease in Brazilian patients awaiting kidney transplant. Transplantation proceedings. 2008;40(5):1333-1336. https://doi.org/10.1016/j.transproceed.2008.02.086 PMid:18589099